Neurogenic Ltd. is a clinical-stage diagnostics company developing sensitive immunoassays to facilitate the diagnosis of mental disorders. Neurogenic commented about their working relationship with SYnAbs:
« SYnAbs has done tremendous job to generate a custom monoclonal antibody thanks to their unique multi-species immunization approach. They generated the first worldwide monoclonal antibody against our confidential peptide, discovered and patented by Weizmann Institute of Science. They also demonstrated a great flexibility working with us and dealing with logistic aspects between our respective countries »
Tzvika Tzubery, CSO Neurogenic Ltd
SYnAbs' vision is to fill the gap in the marketplace for innovative antibodies against poor immunogenic compounds and complex antigens. Targeting lipids, peptides, neoepitopes,toxins, epigenetic modifications and polysaccharides, SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat and guinea pig species to generate unique monoclonal antibodies of extreme specificity and higher affinity.
Neurogenic Ltd. is a clinical-stage diagnostics company developing sensitive immunoassays to facilitate the diagnosis of mental disorders. Over the past 25 years, Neurogenic has been collaborating with colleagues from the Weizmann Institute of Science, Rehovot, the Department of Psychiatry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, the Beer Yaakov-Ness-Ziona Mental Health Center, Ness Ziona, the Geha Mental Health Center, Petach Tikva, and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Rabin Medical Center, Petah Tikva, Israel.